When primary antifungal therapy fails.

Published

Journal Article (Review)

The prognosis for persons with invasive fungal infections has improved over the past 2 decades because of the development of new diagnostic tools, a better understanding of the epidemiology and prognostic factors of these infections, and the availability of new antifungal agents. Nevertheless, antifungal therapy failure is still a substantial clinical problem. When this occurs, the clinician is tempted to attribute therapeutic failure to specific drug resistance and then to change therapy or add another antifungal drug to the regimen. However, other factors may play an even greater role in antifungal therapy failure, such as host factors, low concentration of the drug at the site of infection, drug toxicities, wrong diagnosis, and misdiagnosis of failure because of the occurrence of immune reconstitution inflammatory syndrome. In this review, we discuss the differential diagnosis and management of antifungal therapy failure in invasive mycoses, to help clinicians appreciate the meaning of primary antifungal therapy failure.

Full Text

Duke Authors

Cited Authors

  • Nucci, M; Perfect, JR

Published Date

  • May 1, 2008

Published In

Volume / Issue

  • 46 / 9

Start / End Page

  • 1426 - 1433

PubMed ID

  • 18419447

Pubmed Central ID

  • 18419447

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1086/587101

Language

  • eng

Conference Location

  • United States